Reagent manufacturing for a novel CRISPR-based diagnostic SARS CoV-2 test
Since the beginning of the COVID-19 pandemic, PCR assays have been the gold standard for detecting SARS-CoV-2. Mammoth Biosciences (CA, USA) is developing a CRISPR-based diagnostic workflow that aims to reduce the time required for testing while maintaining the gold standard accuracy of PCR.
Mammoth sought a manufacturing partner to scale this workflow to increase both centralized and decentralized testing capacity, strengthening efforts to combat the pandemic.
Read this remarkable case study to see how Mammoth Biosciences leveraged a contract manufacturing organization to accelerate reagent manufacturing to bring their novel SARS-CoV-2 diagnostic kit to market.
This content was provided by Merck.
The life science business of Merck operates as Millipore Sigma in the USA and Canada.